FASCINATION ABOUT CANAGLIFLOZIN

There have been no clinically considerable variations in the pharmacokinetics of either midazolam (CYP3A4 substrate) or repaglinide (CYP2C8 substrate) when applied concomitantly with finerenone. Several doses of forty mg finerenone when-every day had no clinically relevant effect on AUC or Cmax of the BCRP and OATP substrate rosuvastatin.-Common Un